Efficacy of interferon combined with Rebacin in the treatment of patients with persistent cervical high-risk HPV infection and its influence on their immune level
Objective To analyze the clinical efficacy of interferon combined with Rebacin in the treatment of patients with persistent cervical high-risk human papillomavirus (HPV) infection and its influence on their immune level. Methods 240 patients with persistent cervical high-risk HPV infection were divided into an observation group and a control group according to the differences in treatment modalities,with 120 patients in each group. Patients in the control group were treated with recombinant human interferon α-2b suppository 3 d after menstruation,and patients in the observation group were treated with Rebacin on the basis of the control group. Both groups were compared in terms of HPV negative-conversion status after 6 months of follow-up,the incidence of no adverse reactions,and the levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) before and after treatment. Results In terms of treatment efficacy,the observation group had a clearance rate of 78.33％,while the control group had a total clearance rate of only 31.67％. Especially in terms of the complete clearance rate of HPV,the observation group's 66.67％ was significantly better than the control group's 23.33％,and the total clearance rate was also much higher (78.33％ compared to 31.67％),and these differences were statistically significant (P<0.05). Regarding safety,the observation group had a no adverse reaction incidence rate of 70.00％,while the control group had a slightly higher rate of 76.67％. Although the safety performance of the two groups was similar,statistical analysis showed that the difference was not significant (P>0.05). In terms of changes in biomarkers,both groups of patients had significantly lower levels of TNF-α after treatment compared to before treatment,while IL-6 levels were significantly higher than before treatment. It is worth noting that the average level of TNF-α in the observation group (89.32±23.21) ng/L was lower than that in the control group (106.32±22.76) ng/L,while the average level of IL-6 (9.01±3.43)ng/L was higher than that in the control group (6.54±3.32) ng/L,indicating statistically significant differences in biomarkers after treatment (P<0.05). Conclusion Interferon combined with Rebacin can play a good effect in the treatment of patients with persistent cervical high-risk HPV infection,and it has high drug safety and high promotion value.
万方数据
维普
